Agios Pharmaceuticals has made a significant breakthrough in the treatment of sickle cell disease with the presentation of detailed results from its Phase 3 trial of mitapivat. The trial, which involved patients with sickle cell disease, showed that mitapivat resulted in a significant reduction in pain episodes and an increase in haemoglobin levels, a key indicator of the disease's severity.
The trial results, presented at the European Hematology Association (EHA) Congress, have sparked hope for a new treatment option for sickle cell disease, which affects thousands of people in the UK. Sickle cell disease is a debilitating condition that causes red blood cells to break down, leading to episodes of severe pain and fatigue.
According to the Sickle Cell Society, there are over 14,000 people living with sickle cell disease in the UK, with the majority being of African or Caribbean descent. The condition can have a significant impact on a person's quality of life, with many experiencing frequent hospital admissions and reduced life expectancy.
Agios Pharmaceuticals' mitapivat is an oral medication that works by increasing the production of fetal haemoglobin, which is present in healthy red blood cells but is reduced in people with sickle cell disease. The trial results show that mitapivat is effective in increasing fetal haemoglobin levels and reducing the severity of the disease.